Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

    Christopher T Ritchlin, Kavanaugh Arthur, Joseph F Merola et al.  February 08, 2020
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

    Lieven Lagae, Joseph Sullivan, Kelly Knupp et al.  December 17, 2019
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial

    Rima Nabbout, Arun Mistry, Sameer Zuberi et al.  December 02, 2019
    phase 3

    NAYZILAM® (midazolam) CIV

    Seizure Emergencies
    View

    Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial

    James W Wheless, Tze-Chiang Meng, Peter J Van Ess et al.  July 29, 2019
    phase 2

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Safety and tolerability of adjunctive brivaracetam in pediatric patients <16 years with epilepsy: an open-label trial

    Edwin Liu, Deanne Dilley, Belinda McDonough et al.  June 28, 2019
    phase 3

    NAYZILAM® (midazolam) CIV

    Seizure Emergencies
    View

    Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters - a randomized, double-blind, placebo-controlled trial

    Kamil Detyniecki, Peter J Van Ess, David J Sequeira et al.  May 29, 2019
    phase 3

    CIMZIA® (certolizumab pegol)

    Non-radiographic Axial Spondyloarthritis
    View

    A 52-week randomized placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. 

    Deodhar A, Gensler L, Kay J et al.  May 28, 2019
    phase 3

    CIMZIA® (certolizumab pegol)

    Rheumatoid Arthritis
    View

    Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study. 

    Smolen JS, van Vollenhoven RF, Kavanaugh A et al.  April 30, 2019
    phase 1

    BRIVIACT® (brivaracetam) CV

    View

    A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synpatic vesicle glycoprotein 2A binding in healthy volunteers

    Sjoerd J Finnema, Samantha Rossano, Mika Naganawa et al.  March 29, 2019
    phase 1

    FINTEPLA® (fenfluramine)

    Dravet Syndrome, Lennox-Gastaut Syndrome
    View

    A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects

    Brooks Boyd, Steven Smith, Arnold Gammaitoni et al.  October 19, 2018